Timothy Schulz-utermoehl BSc, MSc, PhD

Dr Schulz-Utermoehl has over 18 years experience in the pharmaceutical industry, spanning early and late-stage discovery research and preclinical development. He was a co-founder and director at Polleo Pharma, has held senior roles at Merck, AstraZeneca and Shire and is currently the Director of DMPK and Physical Sciences at Sygnature Discovery. In parallel to his leadership role at Sygnature Discovery, he is also Vice President of Preclinical Development at Chronos Therapeutics and a Co-founder and Director of Belfry Therapeutics.

Dr Schulz-Utermoehl carried out 2 years of post-doctoral research at Novo Nordisk A/S, Denmark and holds a PhD in Biochemistry from Imperial College, a MSc in Toxicology from the Royal Postgraduate Medical School, University of London and a BSc (Hons) in Pharmacology/Physiology from the University of Leeds.